Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
about
Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human HepatocytesA simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.Management of the metabolic effects of HIV and HIV drugs.Risk assessment of mechanism-based inactivation in drug-drug interactions.Treatment of dyslipidaemia in HIV-infected persons.Strategies for management and treatment of dyslipidemia in HIV/AIDS.Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjectsComparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087A review of nelfinavir for the treatment of HIV infection.Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis.Antiretroviral treatment of HIV infection: Swedish recommendations 2007.The role of cytochrome P450 in antiretroviral drug interactions.Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.Treatment of HIV infection: Swedish recommendations 2009.Treatment of dyslipidemia in HIV-infected patients.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Treatment of dyslipidemia in HIV.Antiretroviral treatment for HIV infection: Swedish recommendations 2016.Evidence-based review of statin use in patients with HIV on antiretroviral therapy.Hyperlipidemia in HIV-positive patients receiving antiretrovirals.Symptomatic orthostasis with extended-release nifedipine and protease inhibitors.Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the
P2860
Q28547949-35DD410B-8142-443F-A685-ECA3B279F45DQ34514087-8CB963C6-3833-4EEC-8DCA-9353AF9CB3F3Q34599850-A5801CCD-5AF5-447D-A6B5-F3A8C66B16DCQ36021411-6A50E3CE-6ECC-463E-9AC0-9401C0F77F89Q36174265-E5069171-ADA2-43B7-9CC2-3C72ACA1F9B5Q36222023-735F007B-EC18-4F08-8F7B-655ADCEF3243Q36336563-2F14856F-01B0-4349-9299-A52EF91E5851Q36491897-624E1F90-BFA4-422E-9F79-7E3FACCA1211Q36528535-BFC2F886-EE63-4FE5-99B0-CCB9C8C29EA3Q36546278-18E0FE62-E141-43CA-AD96-319462DD441FQ36668917-2394F61C-C47F-4172-9BB5-657D2C59F423Q36852859-2682DA1E-528D-42EB-B16C-10768A290070Q36909336-5E2D5DBD-6E85-48C6-BB1B-D64210A38710Q37203653-352D0EE3-0BE6-400B-9873-9C47366C0E96Q37392745-D00447D2-EC7F-44F4-A7A5-A38025985EAEQ37634509-6E5E7DEE-6C38-4AD3-A665-FCE0E55B82CDQ37756963-2CA28E40-ED44-4756-882F-92C533E4706FQ38109095-777DE674-CCC6-4752-B1C5-CC76CA6D80FAQ38363531-B27CA86C-24A0-4737-8F71-B20BAB1366C5Q40470257-FC051283-13E2-4CA6-A0DE-2A8DBE273F93Q42656331-C023E0A1-25D0-4B8F-B654-97278E83D723Q43936404-9E75825B-443D-478C-BC73-7282CD599AB0Q44186647-7C013783-3537-4D17-ADB3-EE5045CAA3D7Q44200949-94F10317-B111-4B9D-BB7D-492FDC6757E9Q45230084-B818E4DE-F15C-4C9A-B9CF-F99ECE3773A2Q45403391-0E7E3163-08D3-4923-AB1C-97BAE4A018F4Q46711334-C05241B1-DBBD-4364-A367-38F7E9F3F336Q47695462-6EBC375A-CA5A-4586-B980-B565DBDA1A0EQ50668713-EA214C8A-D5C6-4B65-8958-ED3F2D1B07FCQ58375437-AC3EB0CB-3C15-41C3-8E8B-C3E324497B0D
P2860
Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacokinetic interactions b ...... atorvastatin and simvastatin.
@ast
Pharmacokinetic interactions b ...... atorvastatin and simvastatin.
@en
type
label
Pharmacokinetic interactions b ...... atorvastatin and simvastatin.
@ast
Pharmacokinetic interactions b ...... atorvastatin and simvastatin.
@en
prefLabel
Pharmacokinetic interactions b ...... atorvastatin and simvastatin.
@ast
Pharmacokinetic interactions b ...... atorvastatin and simvastatin.
@en
P2093
P2860
P1476
Pharmacokinetic interactions b ...... atorvastatin and simvastatin.
@en
P2093
J H Lillibridge
M D Schultz-Smith
P2860
P304
P356
10.1128/AAC.45.12.3445-3450.2001
P407
P577
2001-12-01T00:00:00Z